Samah Algharib | Immunotherapy | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Samah Algharib — Mississippi State University, United States

Samah Algharib
Affiliation Mississippi State University
Country United States
Scopus ID 57211476541
Documents 42
Citations 1,190
h-index 17
Subject Area Immunotherapy
Event International Top Pharmaceutical Awards
ORCID 0000-0002-3336-2855

Samah Algharib is affiliated with Mississippi State University and works within the broad research area of immunotherapy. The documented research record includes studies addressing antibacterial treatment strategies and veterinary infectious disease, including responsive nanogels, controlled-release hydrogels, and diagnostic perspectives related to bovine mastitis. [1] [2] [3]

Abstract

Samah Algharib, affiliated with Mississippi State University, is associated with research spanning immunotherapy, antibacterial treatment strategies, drug delivery, and veterinary infectious disease. The documented publication record includes investigations of pH- and gelatinase-responsive florfenicol nanogels against Staphylococcus aureus, slow-release florfenicol hydrogels for intestinal bacterial infections, and contemporary approaches to bovine mastitis diagnosis. These studies collectively address therapeutic delivery, antimicrobial effectiveness, controlled release, and disease identification. The supplied research profile records 42 documents, 1,190 citations, and an h-index of 17, providing bibliometric context for the recognition of research activity in pharmaceutical and biomedical applications. [1] [2] [3]

Keywords

Immunotherapy; antibacterial therapy; florfenicol; nanogels; hydrogels; controlled drug release; Staphylococcus aureus; bovine mastitis; veterinary medicine; pharmaceutical research.

Introduction

Research associated with Samah Algharib addresses biomedical and pharmaceutical questions involving antimicrobial treatment and disease management. Published work examines responsive florfenicol nanogels and hydrogels designed to improve therapeutic delivery, while related veterinary research considers contemporary diagnostic approaches for bovine mastitis. These topics connect pharmaceutical formulation with infectious-disease applications. [1] [2] [3]

Research Profile

The supplied profile identifies immunotherapy as the principal subject area, alongside research themes involving antimicrobial agents, drug-delivery systems, bacterial infections, and veterinary health. The publications demonstrate attention to formulation characteristics, release behavior, antibacterial activity, and diagnostic considerations, providing a multidisciplinary context for pharmaceutical and biomedical investigation. [1] [2] [3]

Research Contributions

The documented studies contribute to research on responsive and controlled antimicrobial delivery. One study investigates pH- and gelatinase-responsive florfenicol nanogels against Staphylococcus aureus, while another examines slow-release florfenicol hydrogels for intestinal bacterial infections. Related work reviews concepts and advances in bovine mastitis diagnosis, connecting treatment research with disease detection. [1] [2] [3]

Publications

The supplied publication set includes research on enhanced antibacterial effects of pH/gelatinase-responsive florfenicol nanogels, manipulated slow release of florfenicol hydrogels, and basic concepts and recent advances in bovine mastitis diagnosis. These publications collectively reflect research interests spanning pharmaceutical formulation, antimicrobial intervention, controlled release, veterinary disease management, and diagnostic science. [1] [2] [3]

Research Impact

The supplied bibliometric profile records 42 documents, 1,190 citations, and an h-index of 17. These indicators provide quantitative context for the reach of the indexed research record, while the cited publications demonstrate applications in antimicrobial treatment, drug delivery, and veterinary diagnostics. Bibliometric measures should be interpreted alongside publication quality and research context. [1] [2] [3]

Award Suitability

For an Innovative Research Award, the documented work provides evidence of research involving responsive nanogels, controlled-release hydrogels, antibacterial treatment, and veterinary diagnostic perspectives. The combination of formulation-oriented pharmaceutical research and infectious-disease applications demonstrates identifiable innovation themes that can be considered alongside the supplied publication record, citation indicators, affiliation, and the specific criteria established by the awarding organization. [1] [2] [3]

Conclusion

Samah Algharib’s documented research profile encompasses immunotherapy-related interests, antimicrobial delivery, florfenicol formulations, bacterial infection treatment, and bovine mastitis diagnostics. The supplied record combines publication activity with reported citation indicators and research addressing practical biomedical and veterinary challenges. These materials provide a structured basis for academic recognition under the stated Innovative Research Award category. [1] [2] [3]

References

  1. Enhanced antibacterial effect of pH/gelatinase-responsive florfenicol nanogels against Staphylococcus aureus. (2025). PubMed.
    https://pubmed.ncbi.nlm.nih.gov/40292404/
  2. Manipulated slow release of florfenicol hydrogels for effective treatment of anti-intestinal bacterial infections. (n.d.). International Journal of Nanomedicine, Dove Medical Press.
    https://www.dovepress.com/manipulated-slow-release-of-florfenicol-hydrogels-for-effective-treatm-peer-reviewed-fulltext-article-IJN
  3. Basic concepts, recent advances, and future perspectives in the diagnosis of bovine mastitis. (2023). Journal of Veterinary Science. https://doi.org/10.4142/jvs.23147
    https://vetsci.org/DOIx.php?id=10.4142/jvs.23147

Mohamed Husseiny Elsayed | Immunotherapy | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Mohamed Husseiny Elsayed
Beckman Research Institute of City of Hope

Mohamed Husseiny Elsayed
Affiliation Beckman Research Institute of City of Hope
Country United States
Scopus ID 8580986700
Documents 65
Citations 6,388
h-index 28
Subject Area Immunotherapy
Event Name International Top Pharmaceutical Awards
ORCID 0000-0002-3470-2858

The Innovative Research Award recognizes distinguished scientific achievements that contribute to the advancement of biomedical and pharmaceutical sciences. Mohamed Husseiny Elsayed has developed a research profile characterized by sustained contributions to immunotherapy, translational oncology, and therapeutic innovation. His scholarly output has supported the understanding of immune-mediated mechanisms and their application in clinical research environments.[1]

Abstract

This article presents an academic overview of Mohamed Husseiny Elsayed and his suitability for recognition through the Innovative Research Award. The assessment is based on publication activity, citation performance, research visibility, and contributions to immunotherapy-related investigations. Available scholarly indicators demonstrate consistent engagement with impactful biomedical research and collaborative scientific advancement.[2]

Keywords

Immunotherapy, translational medicine, oncology research, biomedical innovation, pharmaceutical sciences, clinical investigation, scientific impact, therapeutic development.

Introduction

Modern biomedical research increasingly depends on interdisciplinary approaches that integrate molecular biology, immunology, and clinical sciences. Researchers working in these domains contribute to the development of therapeutic strategies designed to address complex diseases. Mohamed Husseiny Elsayed has participated in this evolving scientific landscape through research efforts focused on immunotherapeutic applications and translational outcomes.[3]

Research Profile

The researcher is affiliated with the Beckman Research Institute of City of Hope in the United States. Bibliometric indicators report 65 indexed documents, more than 6,300 citations, and an h-index of 28. These metrics suggest sustained scholarly engagement and measurable visibility within the scientific community, particularly in immunotherapy-related disciplines.[1]

Research Contributions

Research contributions attributed to Mohamed Husseiny Elsayed include studies exploring immune responses, cancer therapeutics, and translational research methodologies. His collaborative publications have supported scientific understanding of treatment optimization and biological mechanisms relevant to disease management. Such work aligns with contemporary priorities in precision medicine and advanced therapeutic development.[4]

Publications

The publication record of Mohamed Husseiny Elsayed includes 65 scholarly documents in immunotherapy and translational oncology, reflecting sustained research productivity, scientific collaboration, and contributions to advancing biomedical knowledge and therapeutic innovation.[4]

Research Impact

Citation activity represents one indicator of scientific influence and knowledge dissemination. With thousands of citations recorded across indexed publications, the researcher demonstrates meaningful engagement from the academic community. The observed citation profile suggests that published findings have contributed to ongoing discussions and developments within biomedical research fields.[3]

Award Suitability

Evaluation for the Innovative Research Award considers originality, scholarly productivity, scientific influence, and relevance to advancing healthcare knowledge. Based on available academic indicators, Mohamed Husseiny Elsayed demonstrates characteristics commonly associated with recognized research excellence. His publication record, citation performance, and institutional affiliation collectively support consideration within competitive academic recognition programs.[2]

Conclusion

The academic profile presented in this article highlights measurable research activity and scholarly engagement within the field of immunotherapy. Bibliometric indicators, institutional affiliation, and documented scientific contributions collectively illustrate an established research trajectory. These characteristics provide a foundation for recognition within academic and professional award frameworks dedicated to scientific innovation.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Mohamed Husseiny Elsayed, Author ID 8580986700. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=8580986700
  2. ORCID. (n.d.). Researcher Profile: Mohamed Husseiny Elsayed.
    https://orcid.org/0000-0002-3470-2858
  3. Cobb, J., Rawson, J., Gonzalez, N., Kandeel, F., & Husseiny, M. I. (n.d.). Oral tolerogenic vaccine combined with gastrin restores immune tolerance and beta-cell function in NOD mice with type 1 diabetes.
    https://pubmed.ncbi.nlm.nih.gov/41635853/
  4. Singer, M., Hamdy, R., Ghonaim, J.H., & Husseiny, M.I. Metabolic Imbalance in Immune Cells in Relation to Metabolic Disorders, Cancer, and Infections.
    https://link.springer.com/chapter/10.1007/978-981-96-1305-2_9

Denise Faustman | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Denise Faustman | Immunotherapy | Best Researcher Award

Associate Professor of Medicine at Harvard Medical School  | United States

Dr. Denise Faustman is a physician-scientist recognized for her pioneering work in immunology, autoimmunity, and type 1 diabetes research. She serves as Director of the Immunobiology Laboratory at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. Her career bridges clinical medicine, molecular biology, and translational research, with a focus on advancing novel therapies for autoimmune diseases. Dr. Faustman has significantly contributed to understanding immune tolerance, vaccine-based interventions, and the role of BCG vaccination in autoimmune modulation. She is widely respected for her leadership, scientific advisory roles, and commitment to women’s health and immunological innovation.

Publication Profile 

Scopus

Education

Dr. Denise Faustman earned a B.S. in Zoology and Chemistry from the University of Michigan, followed by an M.D. and Ph.D. in Molecular and Cellular Biology from Washington University School of Medicine in St. Louis. She completed her postdoctoral training in transplantation immunology at Washington University before pursuing clinical training in internal medicine and endocrinology at Massachusetts General Hospital and Harvard Medical School. Her combined training in medicine, molecular biology, and immunology has uniquely positioned her to integrate clinical insights with advanced laboratory science, fueling her translational research on autoimmunity, immunotherapy, and novel strategies for the treatment of chronic diseases.

Experience 

Dr. Denise Faustman has built a distinguished career at Harvard Medical School and Massachusetts General Hospital, where she directs the Immunobiology Laboratory. Her academic roles span from Instructor to Associate Professor of Medicine, combined with leadership in clinical and translational immunology. She has served on numerous national and international scientific committees, including advisory roles at the FDA, NIH, NAS, and Institute of Medicine. As a physician-scientist, she bridges patient care with laboratory innovation, advancing novel treatments for autoimmune diseases. She has also provided scientific leadership for biotech companies, foundations, and research councils, shaping biomedical policy, discovery, and translational impact.

Awards and Honors 

Dr. Denise Faustman contributions have been recognized through prestigious appointments and leadership roles. She has served as Chair and Board Member of the Society for Women’s Health Research, Advisory Committee Member for the FDA, and Chair of national immunology and autoimmunity symposia. She has been elected to scientific advisory boards for biotechnology companies and foundations worldwide, including Sjögren’s Syndrome Foundation and Farallone Therapeutics. Her expertise has been sought by NASA, NIH, and the Department of Defense for defining priorities in immunology, vaccine safety, and women’s health. These roles reflect her influence, innovation, and leadership in advancing immunological and biomedical sciences.

Research Focus 

Dr. Denise Faustman research centers on autoimmunity, immune regulation, and translational immunotherapy. Her laboratory is internationally recognized for pioneering studies on immune tolerance and the use of BCG vaccine as a potential therapy for type 1 diabetes. She investigates mechanisms of T cell regulation, biomarkers for autoimmune progression, and pathways of immune modulation to translate discoveries into clinical applications. Her work bridges fundamental immunology with patient-centered research, aiming to develop safe, effective, and durable treatments for chronic autoimmune diseases. By integrating laboratory science, clinical trials, and translational medicine, Dr. Faustman is shaping innovative therapeutic strategies with global health impact.

Publication Top Notes

The spleen assumes a major role in blood glucose regulation in type 1 diabetes patients treated with BCG

Late in the US pandemic, multi-dose BCG vaccines protect against COVID-19 and infectious diseases

Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer

Association of BCG Vaccine Treatment with Death and Dementia in Patients with Non-Muscle-Invasive Bladder Cancer

TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4+Foxp3+ regulatory T cells

Letter to the Editor Regarding “The Non-Significant Benefit of BCG Vaccination for the Treatment of Iranian Patients with Type 1 Diabetes up to 48 Weeks: A Controversial Result”

The benefits of clustering in TNF receptor superfamily signaling

Bacille Calmette Guerin (BCG) and prevention of types 1 and 2 diabetes: Results of two observational studies

BCG vaccinations drive epigenetic changes to the human T cell receptor: Restored expression in type 1 diabetes

Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Published on by Top Pharmaceutical

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Assist. Prof. Dr. Konstantinos Tsapakidis, University Hospital Of Larissa, Greece

Assist. Prof. Dr. Konstantinos Tsapakidis 🎓👨‍⚕️ is an esteemed Medical Oncologist at the University of Thessaly, Greece. With a Ph.D. focused on prostate cancer research, he holds European Certification in Medical Oncology 🏅. Since 2018, he has been actively involved in clinical oncology, teaching postgraduate courses on cancer, diet, and immunotherapy 🍽️🧬. Dr. Tsapakidis has authored numerous impactful publications 📚, contributing significantly to cancer diagnostics and treatment. Passionate about education, he trains residents and nurses, advancing oncology knowledge. His expertise includes systemic antineoplastic therapies and immune-oncology 🌟.

Publication Profile

Orcid

Education

Assist. Prof. Dr. Konstantinos Tsapakidis 🎓 is a dedicated Medical Oncologist with an impressive educational background. He earned his Biology degree from Aristotelian University of Thessaloniki 🧬 (1998–2002) and completed his Medicine degree at the University of Thessaly 🏥 (2003–2007). Dr. Tsapakidis achieved his Ph.D. with excellence (2005–2012), researching prostate cancer’s cell-cycle and apoptosis mechanisms 🔬. He specialized in Medical Oncology in 2017 🎯 and obtained the prestigious European Certification in Medical Oncology in 2018 🏅. He also enhanced his expertise through an Immune-Oncology e-learning program at the University of Piraeus in 2017–2018 💻.

Experience

Assist. Prof. Dr. Konstantinos Tsapakidis 💼 has extensive medical oncology experience. Since February 2025, he serves as Assistant Professor at the University of Thessaly 🎓. From 2018 to 2025, he worked as Consultant in Medical Oncology at University Hospital of Larissa 🏥. Previously, he was a University Scholar and Fellow Consultant there (2017–2018) 👨‍⚕️. He completed his residency in Medical Oncology (2014–2017) and earlier trained in Internal Medicine and Hematology at Larissa hospitals 🩺. Between 2008–2009, he was a Scientific Associate in Medical Oncology, laying a strong foundation for his clinical career 🔬.

Research Focus

Assist. Prof. Dr. Konstantinos Tsapakidis’s research focus lies primarily in Medical Oncology with a strong emphasis on cancer diagnosis, treatment, and immunotherapy. 🧬🩺 His work explores various cancer types including lung cancer, breast cancer, sarcomas, and rare cancers, investigating immunotherapy responses, molecular diagnostics, and tumor behavior. 🔬💉 He is particularly involved in studying biomarkers like PD-1/PD-L1, immune cell profiling, and novel therapeutic approaches to improve patient outcomes. 🧪⚕️ His research also covers cancer-associated complications like thrombosis and metastatic disease. Overall, his contributions advance personalized oncology care and innovative cancer treatment strategies.

Publication Top Notes

Pseudomyxoma Peritonei: A Challenging Clinical Diagnosis. Case Report and Review of the Literature

The Impact of Expert Pathology Review and Molecular Diagnostics on the Management of Sarcoma Patients: A Prospective Study of the Hellenic Group of Sarcomas and Rare Cancers

Pre-Existing Immunity Predicts Response to First-Line Immunotherapy in Non-Small Cell Lung Cancer Patients

ES-SCLC Patients with PD-L1+ CTCs and High Percentages of CD8+PD-1+T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

Combinatorial analysis of CD4<SUP>+</SUP>Tregs and CD8<SUP>+</SUP>Teff to predict response to ICI in patients with ES-SCLC

Metachronous Single Pulmonary Metastasis of Prostate Cancer: Report of a Rare Case and Literature Review

SYNCHRONOUS DIAGNOSIS OF TESTICULAR AND THYROID CANCER IN A YOUNG MALE

A Proposed Nomogram Model for Recurrence of Non-Muscle Invasive Bladder Carcinoma COMMENT

Metastatic rectal cancer in the ampulla of Vater: A unique case

Radiotherapy and Breast Reconstruction: What Is the Ideal Timing? A Narrative Review

Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden

Prof. Peng SHI|Immunotherapy|Best Researcher Award

Published on by Top Pharmaceutical

Prof. Peng SHI-Immunotherapy-Best Researcher Award

Prof. Peng SHI atCity University of Hong ,Hong Kong

Author Profile

Orcid

Early Academic Pursuits 🎓

Peng Shi’s academic journey began with a solid foundation in electrical engineering, earning a Bachelor of Engineering degree from Wuhan University, China, in 2002. His keen interest in blending engineering with biological systems led him to pursue advanced studies in biomedical engineering at Columbia University, USA, where he earned both an M.Phil. in 2006 and a Ph.D. in 2009. At Columbia, Dr. Shi honed his expertise in interdisciplinary research, laying the groundwork for his future contributions to translational neuro-engineering and bioelectronics.

Professional Endeavors 👨‍🏫

Dr. Shi’s career reflects a trajectory of academic excellence and innovation. After completing his Ph.D., he served as a Postdoctoral Fellow at the Department of Electrical Engineering, Massachusetts Institute of Technology (MIT), USA (2010–2011), where he worked alongside leading researchers to advance the frontiers of bioelectronics and synthetic biology.

In 2011, Dr. Shi joined the Department of Biomedical Engineering at the City University of Hong Kong as an Assistant Professor. His dedication and groundbreaking work earned him an early promotion to Associate Professor (with tenure) in 2016 and subsequently to Full Professor in 2020. Notably, these advancements highlight his exceptional contributions to his field within a remarkably short timeframe.

Contributions and Research Focus 🔬

Dr. Shi is a pioneer at the intersection of neuroscience and engineering, leveraging cutting-edge methodologies like nano-/micro-fabrication, bioelectronics, synthetic biology, high-resolution microscopy, and artificial intelligence. His research addresses critical challenges in translational neuro-engineering, emphasizing the development of high-throughput technologies and bioelectronic platforms to create innovative therapeutic systems.

His prolific output includes more than 90 publications in prestigious journals such as Nature Reviews Materials, Nature Biomedical Engineering, PNAS, Science Advances, and Advanced Materials. These works underscore his influence in fields spanning materials science, bioengineering, and neurotechnology. Beyond academic publishing, Dr. Shi has filed 18 patents, with several granted in the US and China. Some of these patents have served as the technological foundation for two biotech spin-offs, ANRim Biotechnology Limited and Electro-Ohmics, exemplifying the translational impact of his research.

Accolades and Recognition 🏅

Dr. Shi’s excellence in research and innovation has been recognized with numerous prestigious awards and appointments:

  • 2015: Awarded the 1000 Young Talent Program by the National Natural Science Foundation of China (NSFC), a testament to his exceptional potential in scientific leadership.
  • 2018: Received the Special Recognition for Young Scholars from the World Cultural Council for his contributions to advancing global scientific understanding.
  • 2022: Appointed as Associate Editor of Brain Research (Elsevier), reflecting his influence in shaping the field of neuroscience.
  • 2023: Selected for the Biology and Medicine Panel of the Hong Kong RGC Joint Research Schemes, recognizing his leadership in biomedical research.

Dr. Shi has also delivered over 100 invited talks at global conferences, workshops, and academic institutions, further solidifying his reputation as a thought leader.

Impact and Influence 🌍

Dr. Shi’s innovations have a far-reaching impact, bridging the gap between basic research and clinical applications. His high-throughput bioelectronic platforms are revolutionizing therapeutic strategies, particularly in the realm of neuro-engineering. The biotech companies he co-founded, such as ANRim Biotechnology Limited, have secured significant funding, including RMB15M in angel investments, and are valued at HKD70M, demonstrating his success in translating academic research into viable commercial solutions.

As a grant referee for organizations like the NSFC, European Research Council, and Hong Kong UGC, Dr. Shi contributes to shaping the global research landscape. His expertise is further acknowledged through his role as a manuscript reviewer for leading publishers such as Nature, Wiley, and Elsevier.

Legacy and Future Contributions 🌟

Dr. Peng Shi’s work is paving the way for the next generation of therapeutic technologies and bioelectronic systems. By fostering interdisciplinary collaborations and mentoring emerging scholars, he is shaping the future of biomedical engineering. His patents and spin-offs ensure that his innovations continue to benefit society, bridging the divide between academia and industry.

Looking forward, Dr. Shi is poised to expand his influence through groundbreaking discoveries in synthetic biology, neuro-engineering, and artificial intelligence, driving advancements in healthcare and enhancing human well-being. His legacy will undoubtedly inspire future researchers and innovators, cementing his status as a transformative figure in biomedical engineering.

Notable Publication

Multifunctional Hydrogel Electronics for Closed-loop Antiepileptic Treatment

  • Authors   :Yuan WANG; Guangyu ZHU; Shu Chen; Chenjie Xu; Kai Xie; Jin Qu; Peng SHI; xingdao he
  • Journal    : Science Advances
  • Year         :2024

Few-shot meta-learning applied to whole brain activity maps improves systems neuropharmacology and drug discovery

      • Authors   : Xuan Luo; Yanyun Ding; Yi Cao; Zhen LIU; Wenchong Zhang; Shangzhi Zeng; Shuk Han Cheng; Honglin Li; Stephen J
      • Journal    : iScience
      • Year         :2024

Integrated Piezoelectric Vascular Graft for Continuous Real-Time Hemodynamics Monitoring

  • Authors   : Zhiqiang Ma; Weibin Jia; Jing ZHANG; xingdao he; Shiyuan Liu; Mohamed Elhousseini Hilal; Xiang ZHOU
  • Journal    : Functional Materials
  • Year         :2024

Nanopores-templated CNT/PDMS Microcolumn Substrate for the Fabrication of Wearable Triboelectric Nanogenerator Sensors to Monitor Human Pulse and Blood Pressure

  • Authors   :Tao Zhang; Chuanjie Yao; Xingyuan Xu; Zhibo Liu; Zhengjie Liu; Tiancheng Sun; Shuang Huang.
  • Journal     : Materials Technologies
  • Year         :2024                                                                                                                                                                                                                                                                                                                                                                                                          

Deciphering the Temporal–Spatial Interactive Heterogeneity of Long Non-Coding RNAs and RNA-Binding Proteins in Living Cells at Single-Cell Resolution

  • Authors   : Deyuan Yang; Cheng Li; Yutong Kong; Yian Pei; Bing Miao; Gaole Dai; Pi Ding; Peng Shi; Zixun
  • Journal     : American Chemical Society
  • Year         :2024          

Dr. Annie Zhang|Immunotherapy|Best Researcher Award

Published on by Top Pharmaceutical

Dr. Annie Zhang|Immunotherapy|Best Researcher Award

Dr. Annie Zhang at Cambridge,United States

PROFILE  

 

Scopus

Dr. Annie Zhang embarked on her academic journey with a strong foundation in medicine and public health, earning an MD and an MPH. Her dual degrees equipped her with a nuanced understanding of clinical medicine and the critical public health frameworks essential for managing and preventing diseases at both population and individual levels. Driven by a commitment to advancing therapeutic options and improving patient outcomes, she honed her knowledge in both biostatistics and epidemiology. These skills have been foundational throughout her career, particularly in her roles focused on evidence generation and clinical research.

🌟 Professional Endeavors

Throughout her distinguished career, Dr. Zhang has held senior roles at prominent pharmaceutical companies, demonstrating her expertise in medical affairs, clinical research, and strategic evidence generation.

  1. Sanofi, Cambridge, MA
    As the Global Senior Medical Director in Immunology & Dermatology since 2018, Dr. Zhang has led impactful initiatives in Medical Evidence Generation within Global Medical Affairs. Her key achievements include winning Sanofi’s “Best of Best” award in 2023 and receiving a 1st Place Poster award at the American Academy of Dermatology (AAD) conference in 2024 for her work’s scientific importance. Her leadership has propelled Sanofi’s immunology initiatives, particularly through studies such as PEDISTAD and INFANTSTAD, which focus on disease modification and prevention of the atopic march.
  2. Apellis, Waltham, MA
    In her tenure as Medical Director at Apellis from January 2017 to December 2017, Dr. Zhang was responsible for strategic planning and clinical development in hematology, overseeing Phase II and III studies in conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA). Her role included extensive interaction with thought leaders and the clinical team to design and optimize trial strategies.
  3. Biogen, Cambridge, MA
    From 2009 to 2016, Dr. Zhang held several pivotal roles at Biogen, advancing from Medical Director in Global Medical Affairs to leading biostatistical teams for key drug programs like Tecfidera. She worked on Tysabri’s lifecycle management, supporting clinical trial design, data generation, and publication strategies, especially in multiple sclerosis (MS). Her expertise in biostatistics and clinical research design strengthened Biogen’s data-driven approaches, particularly in Phase III and IV clinical trials.
  4. PAREXEL International, Lowell, MA
    Dr. Zhang worked as a Senior Biostatistician at PAREXEL from 2007 to 2009, leading biostatistical tasks across diverse therapeutic areas, including oncology, CNS disorders, and cardiovascular disease. Her meticulous approach ensured the quality and accuracy of statistical reports for clinical trials, contributing to numerous successful projects within the biostatistics team.
  5. New England Research Institutes, Watertown, MA
    Early in her career, Dr. Zhang served as an Associate Research Scientist at NERI from 2000 to 2007, where she conducted critical statistical analyses for clinical research, laying the groundwork for her later expertise in biostatistics and clinical study design.

💡 Contributions and Research Focus

Dr. Zhang’s research has centered around dermatology, immunology, and hematology. At Sanofi, her work in immunology has led to groundbreaking insights on skin barrier integrity and neuroimmune function, providing essential evidence for the prevention of atopic march. She has also driven significant advancements in real-world evidence generation, particularly in cross-functional collaboration with global market access and regulatory teams, demonstrating her strategic alignment with organizational goals and patient needs.

🏆 Accolades and Recognition

Dr. Zhang’s achievements have earned her numerous accolades, including the prestigious “Best of Best” award at Sanofi in 2023. In addition, she received 1st Place at the AAD 2024 Poster Award for her study on skin barrier health. Her work has also made her one of the most-read and cited authors in Allergy and Pediatric Dermatology in 2024, underscoring her impact and visibility in her field.

🌐 Impact and Influence

Through her extensive collaborations, Dr. Zhang has influenced clinical practices and regulatory frameworks worldwide. Her involvement in key study proposals and evidence generation initiatives has significantly impacted the medical community’s understanding of dermatological conditions. Her efforts in strategic planning, data generation, and cross-functional teamwork have positioned her as an influential figure in dermatology and immunology, particularly in advancing therapies that meet rigorous safety and efficacy standards.

🌱 Legacy and Future Contributions

Dr. Zhang’s legacy lies in her innovative approach to medical evidence generation and her unwavering commitment to patient-centered research. Her leadership in studies such as PEDISTAD and INFANTSTAD has set new standards for clinical research in dermatology and immunology. As she continues her work at Sanofi, Dr. Zhang’s contributions promise to expand the understanding and treatment of complex immunological conditions, impacting healthcare practices on a global scale.

Through her career, Dr. Zhang has exemplified excellence, dedication, and a strategic vision, ensuring her place as a respected leader in the pharmaceutical and clinical research sectors. Her ongoing work will undoubtedly continue to shape medical innovations and patient care improvements, leaving a lasting legacy in the fields of immunology and dermatology.

🎓Publication 

Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM

  • Authors   :Fox, R.J., Gold, R., Phillips, J.T., … Zhang, A., Marantz, J.L.
  • Journal    :Neurology and Therapy
  • Year         :2017

Number Needed to Treat in Multiple Sclerosis Clinical Trials

  • Authors   : Okwuokenye, M., Zhang, A., Pace, A., Peace, K.E.
  • Journal    :Neurology and Therapy
  • Year         :2017

Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis

  • Authors   : Fox, R.J., Chan, A., Zhang, A., … Edwards, M.R., Marantz, J.L
  • Journal    :Current Medical Research and Opinion
  • Year         :2017

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies

  • Authors   :Gold, R., Giovannoni, G., Phillips, J.T., … Zhang, A., Marantz, J.L.
  • Journal    :Neurology and Therapy
  • Year         :2016

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS

  • Authors   :Spelman, T., Kalincik, T., Jokubaitis, V., … Trojano, M., Butzkueven, H.
  • Journal    :Neurology: Clinical Practice
  • Year         :2016